IP Library Granted Patent US 11,447,810
Granted Patent B2
US 11,447,810 · App. 17/163,016 · Granted Sep 20, 2022

Compositions and methods for the production of compounds

Inventors: Brian R. Bowman (New Rochelle, NY); Joshua A. V. Blodgett (Webster Groves, MO); Gregory L. Verdine (Boston, MA); Daniel C. Gray (Medford, MA); Jay P. Morgenstern (Boston, MA); Lucy Foulston (Medford, MA); Keith Robison (Andover, MA)
Assignee: Ginkgo Bioworks, Inc.
C12P35/00C07K14/36C12N15/52C12N15/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,447,810
App. No.
17/163,016
Granted
Sep 20, 2022
Kind
B2
Abstract

The present disclosure provides nucleic acids encoding a Large ATP-binding regulator of the LuxR family (LAL) of transcription factors, vectors and host cells including such nucleic acids, and methods for producing compounds (e.g., polyketides or β-lactam compounds) with such nucleic acids, vectors, and/or host cells.

Claims (31)

1. A method of producing a compound, the method comprising:

(a) providing a genetically modified host cell comprising:

(i) a nucleic acid encoding a recombinant Large ATP-binding regulator of the LuxR family (LAL) that is heterologous to the host cell; and

(ii) a nucleic acid comprising an LAL binding site that is heterologous to the host cell, wherein the LAL binding site is operably linked to an open reading frame encoding a compound-producing protein, and wherein binding of the recombinant LAL to the LAL binding site promotes expression of the compound-producing protein; and

(b) culturing the host cell under conditions suitable to allow expression of a compound by the compound-producing protein;

thereby producing a compound.

2. The method of claim 1 , wherein the host cell naturally lacks an LAL or the host cell naturally lacks an LAL binding site.

3. The method of claim 1 , wherein the recombinant LAL comprises a portion having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1.

4. The method of claim 1 , wherein the recombinant LAL comprises a portion having the amino acid sequence of SEQ ID NO: 1.

5. The method of claim 1 , wherein the recombinant LAL has the amino acid sequence of SEQ ID NO: 1.

6. The method of claim 1 , wherein the host cell has been modified to enhance expression of the compound-producing protein by (i) deletion of an endogenous gene cluster which expresses an endogenous compound-producing protein; (ii) insertion of a heterologous gene cluster which expresses a heterologous compound-producing protein; (iii) exposure of the host cell to an antibiotic challenge; and/or (iv) introduction of a heterologous promoter that results in an at least 2-fold increase in expression of a compound produced by the compound-producing protein compared to the expression of the compound when the homologous promoter has not been replaced.

7. The method of claim 1 , wherein:

the nucleic acid further comprises one or more additional LAL binding sites;

at least one of the LAL binding sites is in a promoter; or

the nucleic acid further comprises a gene encoding an LAL.

8. The method of claim 7 , wherein:

the gene encoding an LAL is under the control of a promoter comprising an LAL binding site; or

at least one of the LAL binding sites is in a promoter.

9. The method of claim 8 , wherein at least one of the LAL binding sites is in a promoter and the promoter is a bidirectional promoter.

10. The method of claim 1 , wherein the LAL binding site comprises a sequence having no more than one insertion, deletion, or substitution with respect to the nucleic acid sequence of SEQ ID NO: 2 and/or comprises the nucleic acid sequence of SEQ ID NO: 3, and wherein the LAL comprises a portion having at least 90% sequence identity to the amino acid sequence of SEQ ID NO: 1.

11. The method of claim 10 , wherein the LAL comprises a portion having the amino acid sequence of SEQ ID NO: 1.

12. The method of claim 10 , wherein the LAL has the amino acid sequence of SEQ ID NO: 1.

13. The method of claim 10 , wherein the LAL binding site comprises the nucleic acid sequence of SEQ ID NO:2.

14. The method of claim 10 , wherein the LAL binding site comprises the nucleic acid sequence of SEQ ID NO:3.

15. The method of claim 10 , wherein:

the nucleic acid further comprises one or more additional LAL binding sites; or

the gene encoding the LAL is under the control of a promoter comprising an LAL binding site.

16. The method of claim 15 , wherein at least one of the LAL binding sites is in a promoter.

17. The method of claim 16 , wherein the promoter is a bidirectional promoter.

18. The method of claim 1 , wherein the compound-producing protein is a polyketide synthase, a β-lactam compound-producing protein, or a non-ribosomal peptide synthase.

19. The method of claim 1 , wherein the compound is a polyketide, a β-lactam compound, or a non-ribosomal peptide.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2021
From: BOWMAN, BRIAN R.; BLODGETT, JOSHUA A.V.; VERDINE, GREGORY L.; GRAY, DANIEL C.; MORGENSTERN, JAY P.; FOULSTON, LUCY; ROBISON, KEITH
To: WARP DRIVE BIO, LLC
Reel/Frame 056044/0381 →
MERGER Recorded Apr 26, 2021
From: WARP DRIVE BIO, LLC
To: WARP DRIVE BIO, INC.
Reel/Frame 056044/0390 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2021
From: WARP DRIVE BIO, INC.
To: GINKGO BIOWORKS, INC.
Reel/Frame 056044/0406 →
Continuity (3)
Division 16093074
Provisional Application 62321439 · Apr 12, 2016
Related Publication 20210238646A1 · Aug 5, 2021